Infections, Injection-related Infections, Peer Support, People Who Infect Drugs (PWID)
Conditions
Brief summary
People who inject drugs are at risk of injection-related infections, like abscesses or infective endocarditis. The Injection-Related InfectionS (IRIS) program hopes to improve treatment for participants by providing a low-barrier, one-stop shop model for people who inject drugs who experience injection-related infections to access more holistic and compassionate care. IRIS is a non-randomized clinical trial, meaning that it offers a specific program to eligible patients. This program offers care for substance use and infectious disease with additional peer support and systems navigation, if interested. The investigators anticipate enrolling 80 participants in the intervention and will follow participants throughout the infection treatment period (estimated 6-12 weeks). The investigators will collect information at the time of enrolment, at the 6-month mark, and monthly via electronic medical chart review. The investigators will use an interrupted time series analysis to evaluate the impact of the intervention on rates of treatment completion, emergency department visits, hospitalizations, and death, before versus after the intervention.
Interventions
OTHERHolistic injection-related injection treatment
Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.
Sponsors
HAMSMaRT
Keeping Six
YWCA Hamilton
McMaster University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 105 Years
Healthy volunteers
No
Inclusion criteria
* Age 16 or older * Able to provide informed consent * Presenting with a confirmed or suspected injection-related infection (including skin and soft tissue infections, osteomyelitis, infective endocarditis, Hepatitis C, HIV, etc) * History of injection drug use within 3 months of recruitment * Lives in Hamilton, Ontario
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of emergency department visits and hospital readmission | Within 30 days of initial hospital admission or program enrolment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of hospital readmissions specifically for the infection that was the primary reason for program enrolment | Within 90-days of hospital discharge or program enrolment | — |
| Number of emergency department visits | Within 90-days of hospital discharge or program enrolment | — |
| Completion of intended course of treatment for the injection-related infection | Within 6 months of initial hospital admission or program enrolment | Investigators will record whether or not participants have completed the intended course of treatment for their injection-related infection (e.g. completed course of antibiotics - YES or NO). |
| Mortality rates | Within 6-months of hospital discharge or program enrolment | — |
| Rates of program drop-out and reasons for discontinuation | Within 6-months of hospital discharge or program enrolment | — |
| Number of new initiations or record of continuation of substance use treatment | Within 90-days of hospital discharge or program enrolment | — |
Countries
Canada
Contacts
Primary ContactAlisha Atri
Outcome results
None listed